$0.52
4.88% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US00091F1066
Symbol
ABVC
Sector
Industry

ABVC BioPharma Inc Stock price

$0.52
-0.17 24.58% 1M
-0.41 44.17% 6M
-0.64 55.00% YTD
-1.16 68.93% 1Y
-31.08 98.35% 3Y
-66.48 99.22% 5Y
-1,432.14 99.96% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.03 4.88%
ISIN
US00091F1066
Symbol
ABVC
Sector
Industry

Key metrics

Market capitalization $6.77m
Enterprise Value $8.30m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 16.27
P/S ratio (TTM) P/S ratio 13.27
P/B ratio (TTM) P/B ratio 0.79
Revenue growth (TTM) Revenue growth -31.04%
Revenue (TTM) Revenue $510.00k
EBIT (operating result TTM) EBIT $-6.33m
Free Cash Flow (TTM) Free Cash Flow $-2.02m
Cash position $840.00k
EPS (TTM) EPS $-0.90
Short interest 1.94%
Show more

Is ABVC BioPharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

ABVC BioPharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast ABVC BioPharma Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast ABVC BioPharma Inc:

Hold
100%

Financial data from ABVC BioPharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.51 0.51
31% 31%
100%
- Direct Costs 0.17 0.17
62% 62%
33%
0.34 0.34
17% 17%
67%
- Selling and Administrative Expenses 6.42 6.42
10% 10%
1,259%
- Research and Development Expense 0.22 0.22
91% 91%
43%
-6.30 -6.30
33% 33%
-1,235%
- Depreciation and Amortization 0.03 0.03
0% 0%
6%
EBIT (Operating Income) EBIT -6.33 -6.33
33% 33%
-1,242%
Net Profit -8.24 -8.24
33% 33%
-1,616%

In millions USD.

Don't miss a Thing! We will send you all news about ABVC BioPharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ABVC BioPharma Inc Stock News

Neutral
GlobeNewsWire
about one month ago
FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has received a total of $346,000 in lic...
Neutral
GlobeNewsWire
3 months ago
• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) --   ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncol...

Company Profile

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of new drugs and medical devices. The company also integrates research achievements from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. It conducts clinical trials of translational medicine for Proof of Concept and out-licenses it to international pharmaceutical companies. Its products include BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia. The company was founded in 1990 and is headquartered in Fremont, CA.

Head office United States
CEO Uttam Patil
Employees 19
Founded 1990
Website www.abvcpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today